#USA #Plymouth Meeting #Opioid Treatment #BRIXADI #Braeburn

New Insights into BRIXADI® Safety

Braeburn has announced the publication of a pivotal study in The Journal of Substance Use & Addiction Treatment (JSAT) analyzing the safety profile of its medication, BRIXADI®, which is used for treating opioid use disorder. The study specifically investigates adverse events reported in the first 18 months following the U.S. commercial launch of this medication.

Study Overview

The study scrutinizes data submitted to the FDA Adverse Event Reporting System (FAERS), evaluating cases documented during the initial 6, 12, and 18-month intervals post-launch. This retrospective review aims to provide a more comprehensive understanding of the drug's performance in real-world settings compared to data gathered during clinical trials.

Dr. Brian Dawson, Chief Medical Officer at Ideal Option, noted that while clinical trials have traditionally shaped safety profiles, postmarketing data enhances the knowledge available for healthcare practitioners, especially as they observe treatment responses in a broader patient demographic.

Dr. Joshua M. Cohen, the Chief Medical Officer at Braeburn, emphasized that this study's findings are vital for healthcare professionals making informed decisions while managing patients who are grappling with opioid use disorder (OUD). The tangible statistics will contribute to improved patient care and treatment protocols across the country.

About BRIXADI®

BRIXADI® stands out in the class of medications used to address opioid dependency, as it requires patients to be initiated with a single dose of a transmucosal buprenorphine product. This extended-release formulation is designed for subcutaneous use and integrates with a comprehensive treatment plan that includes crucial counseling and psychosocial support.

The drug is available in two specific formulations: the weekly administration of 50 mg/mL buprenorphine and the monthly variant with a higher dosage of 356 mg/mL. These options enable flexibility in treatment, allowing healthcare providers to tailor therapy to individual patient needs.

Important Safety Information

Braeburn also highlighted the critical importance of the BRIXADI REMS program, which ensures that only certified healthcare settings and pharmacies can distribute the medication. This is particularly crucial due to the risk of serious harm or even death associated with intravenous administration of BRIXADI®, which can occlude blood vessels and cause severe tissue damage.

Patients receiving BRIXADI® are advised about potential interactions with narcotics and central nervous system depressants, reinforcing the need for careful monitoring by healthcare providers. Misuse of buprenorphine can lead to serious complications, including respiratory depression and addiction, necessitating a precise evaluation of each patient’s treatment plan and monitoring for signs of potential misuse.

Conclusion

As the healthcare landscape shifts towards more personalized treatment plans for those affected by opioid use disorder, the insights drawn from the new safety analysis of BRIXADI® will prove indispensable. This thorough examination contributes to the growing body of knowledge surrounding opioid treatments and echoes the commitment of Braeburn to improve the quality of care for individuals navigating opioid dependency.

For further details about the study and its findings, the complete research is available at the Journal of Substance Use & Addiction Treatment (JSAT). This publication not only updates current medical discourse but also underlines Braeburn's dedication to supporting effective opioid disorder management through innovative solutions. For more information on BRIXADI®, please visit braeburnrx.com.